As officials from Public Services and Procurement Canada, we can't speak to the strategic innovation fund amounts. For those questions, I would refer you to Innovation, Science and Economic Development Canada.
For the advance purchase agreement, the $150 million advance payment was intended for at-risk manufacturing, meaning activities leading up to the commercial-scale production of the doses that were intended to be done prior to Health Canada authorization. That was to enable Medicago to get doses produced as quickly as possible, so we could get them in the arms of Canadians.
Remembering the context at the time, we know that when we entered into this advance purchase agreement, there were no COVID vaccines approved anywhere in the world.